verapamil has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 13 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have previously generated chronic myeloid leukemia (CML) cell lines resistant to the tyrosine kinase inhibitor imatinib mesylate (STI571), and one line (LAMA84-r) showed overexpression not only of the Bcr-Abl protein but also of Pgp." | 7.72 | MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. ( Belloc, F; Chollet, C; Goldman, JM; Lagarde, V; Mahon, FX; Melo, JV; Moreau-Gaudry, F; Reiffers, J, 2003) |
| " We have previously generated chronic myeloid leukemia (CML) cell lines resistant to the tyrosine kinase inhibitor imatinib mesylate (STI571), and one line (LAMA84-r) showed overexpression not only of the Bcr-Abl protein but also of Pgp." | 3.72 | MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. ( Belloc, F; Chollet, C; Goldman, JM; Lagarde, V; Mahon, FX; Melo, JV; Moreau-Gaudry, F; Reiffers, J, 2003) |
| "Dipyridamole strongly inhibited spontaneous in vitro proliferation of peripheral blood mononuclear cells from patients with acute myelogenous leukaemia (n = 9), chronic myelogenous leukaemia in first chronic phase (n = 4) and blast phase (n = 1)." | 3.68 | Effect of dipyridamole, theophyllamine and verapamil on spontaneous in vitro proliferation of myelogenous leukaemia cells. ( Bruserud, O, 1992) |
| "Curcumin (1) is a secondary metabolite isolated from the turmeric of Curcuma longa L." | 1.46 | A novel curcumin derivative which inhibits P-glycoprotein, arrests cell cycle and induces apoptosis in multidrug resistance cells. ( Correia-da-Silva, M; Lima, RT; Lopes-Rodrigues, V; Oliveira, A; Pinto, M; Sousa, E; Vasconcelos, MH, 2017) |
| "The idarubicin treated subline, K/IDA, was only resistant to taxol but was 12-fold sensitized to etoposide, suggesting that idarubicin had affected topoisomerase II in this subline." | 1.29 | Development of drug resistance is reduced with idarubicin relative to other anthracyclines. ( Davey, MW; Davey, RA; Hargrave, RM; Kidman, AD, 1995) |
| "Pgp was positive in 75% of acute nonlymphoblastic leukemia (ANLL) and 50% of acute lymphoblastic leukemia (ALL)." | 1.28 | P-glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporine A containing protocols. ( Akan, H; Beksaç, M; Ertürk, S; Güneyli, A; Ikizünal, Y; Ilhan, O; Koç, H; Sardaş, OS, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 8 (61.54) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lopes-Rodrigues, V | 1 |
| Oliveira, A | 1 |
| Correia-da-Silva, M | 1 |
| Pinto, M | 1 |
| Lima, RT | 1 |
| Sousa, E | 1 |
| Vasconcelos, MH | 1 |
| Mahon, FX | 1 |
| Belloc, F | 1 |
| Lagarde, V | 1 |
| Chollet, C | 1 |
| Moreau-Gaudry, F | 1 |
| Reiffers, J | 1 |
| Goldman, JM | 1 |
| Melo, JV | 1 |
| Ohtani, H | 2 |
| Ikegawa, T | 2 |
| Honda, Y | 1 |
| Kohyama, N | 1 |
| Morimoto, S | 2 |
| Shoyama, Y | 2 |
| Juichi, M | 1 |
| Naito, M | 3 |
| Tsuruo, T | 3 |
| Sawada, Y | 2 |
| Hargrave, RM | 1 |
| Davey, MW | 2 |
| Davey, RA | 2 |
| Kidman, AD | 2 |
| Maslak, P | 1 |
| Hegewisch-Becker, S | 1 |
| Godfrey, L | 1 |
| Andreeff, M | 1 |
| Marks, DC | 1 |
| Maynadié, M | 1 |
| Matutes, E | 1 |
| Catovsky, D | 1 |
| Ushigome, F | 1 |
| Koyabu, N | 1 |
| Beksaç, M | 1 |
| Akan, H | 1 |
| Koç, H | 1 |
| Ilhan, O | 1 |
| Ertürk, S | 1 |
| Güneyli, A | 1 |
| Ikizünal, Y | 1 |
| Sardaş, OS | 1 |
| Takemura, Y | 1 |
| Koide, Y | 1 |
| Miyachi, H | 1 |
| Shibata, T | 1 |
| Sekiguchi, S | 1 |
| Tukemura, Y | 1 |
| Bruserud, O | 1 |
| Satyamoorthy, K | 1 |
| Chitnis, MP | 1 |
| Pradhan, SG | 1 |
| Advani, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Retrospective Study to Validate Pharmacogenetics Model for Imatinib Metabolism in Patients With Chronic Myeloid Leukemia[NCT01437202] | 100 participants (Actual) | Observational | 2011-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 other studies available for verapamil and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
A novel curcumin derivative which inhibits P-glycoprotein, arrests cell cycle and induces apoptosis in multidrug resistance cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycl | 2017 |
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Death; Cell Div | 2003 |
Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gp-overexpressing K562/ADM cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Su | 2007 |
Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, West | 1995 |
Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemoth | 1994 |
Differentiation and multidrug resistance in response to drug treatment in the K562 human leukaemia cell line.
Topics: Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carr | 1993 |
Quantification of P-glycoprotein in chronic lymphocytic leukemia by flow cytometry.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antibodies, Monoclonal; ATP Binding Cas | 1997 |
Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells.
Topics: Acetates; ATP Binding Cassette Transporter, Subfamily B; Beverages; Blotting, Western; Citrus; Cyclo | 2000 |
Functionally active homodimer of P-glycoprotein in multidrug-resistant tumor cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transpor | 1992 |
P-glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporine A containing protocols.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, | 1992 |
Effect of verapamil on the class I major histocompatibility complex antigen expression in K562 chronic myelogenous leukemia cells treated with recombinant human interferon-gamma.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antibodies, Monoclonal; Blotting, Northern; Calcimyci | 1992 |
Effect of dipyridamole, theophyllamine and verapamil on spontaneous in vitro proliferation of myelogenous leukaemia cells.
Topics: Aminophylline; Blast Crisis; Cell Division; Dipyridamole; Dose-Response Relationship, Drug; Drug Scr | 1992 |
Modulation of mitoxantrone cytotoxicity by verapamil in human chronic myeloid leukemia cells.
Topics: DNA; Drug Synergism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitoxantrone; Tumor C | 1989 |